About this trial
The goal of this clinical trial is to evaluate if caudal dexmedetomidine can provide effective analgesia during inguinoscrotal surgeries in pediatrics, if used caudally alone (and not as an adjunct to caudal bupivacaine).
The main question it aims to answer is:
* Can caudal dexmedetomidine provide effective analgesia? Participants will be pediatrics aged from 1 to 6 years ASA-I and ASA-II undergoing inguinoscrotal surgeries.
\- A total of 50 pediatric patients who will undergo inguinoscrotal surgery will be allocated randomly into 2 equal groups: * Group B (n =25): In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of bupivacaine 0.125 % in a dose of 1ml/kg. * Group D (n =25): In this group, and after injection of general anesthesia, pediatric patients will receive a caudal injection of dexmedetomidine in a dose of 1.5 mcg/kg.
Eligibility criteria
Qualifiers
ASA-I and ASA-II pediatric patients (age :1-6 years old)
Inguinoscrotal surgeries
Disqualifiers
Patient's parent's refusal
Unable to give consent
Known allergy to the study medications
Coagulopathies or on anticoagulant medications
Trial design
Treatments tested in this trial
- Caudal Bupivacaine injection
- Caudal Dexmedetomidine Injection